MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008466:Mechlorethamine / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D012737:Sex Factors; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone